SUNPHARMA:NSE
Sun Pharmaceutical Industries Ltd
1 758,80 ₹
arrow_downward
-0,29%(-5,20) 1D
16 tet, 3:30:00 m.d., GMT+5:30 · INR
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për SUNPHARMA...
Hap
1 762,20 ₹
I lartë
1 764,90 ₹
I ulët
1 743,50 ₹
Kapitalizimi i tregut
4,22 bln
Vëllimi mesatar
1,45 mln
Vëllimi
1,52 mln
Dividendi
0,91%
Dividendi tremujor
4,00 ₹
Data e ndërprerjes së dividendit
7 korr 2026
Raporti çmim/fitim
34,87
Maksimumi 52-javor
2 046,90 ₹
Minimumi 52-javor
1 583,70 ₹
Fitimet për aksion
50,44 ₹
Aksionet në qarkullim
0,00
Numri i punonjësve
47 mijë
Hap
1 762,20 ₹
I lartë
1 764,90 ₹
I ulët
1 743,50 ₹
Kapitalizimi i tregut
4,22 bln
Vëllimi mesatar
1,45 mln
Vëllimi
1,52 mln
Dividendi
0,91%
Dividendi tremujor
4,00 ₹
Data e ndërprerjes së dividendit
7 korr 2026
Raporti çmim/fitim
34,87
Maksimumi 52-javor
2 046,90 ₹
Minimumi 52-javor
1 583,70 ₹
Fitimet për aksion
50,44 ₹
Aksionet në qarkullim
0,00
Numri i punonjësve
47 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
ad-hoc-news.de
·
3 orë më parë
Crisil rates Sun Pharma debt AAA. Sun Pharma stock is valued at INR 4.2 trillion
ad-hoc-news.de
·
23 orë më parë
Analyst consensus puts Sun Pharma stock at INR 2,180.00
Moneycontrol.com
·
2 ditë më parë
Sun Pharma: Tariff relief, innovation brighten growth outlook
ad-hoc-news.de
·
3 ditë më parë
Geojit raises target for Sun Pharma stock to INR 2,070.00
Profili
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
Rreth Sun Pharmaceutical Industries Ltd
Drejtori ekzekutiv-
Punonjësit47 mijë
Themeluar më1983
SeliaGoregaon East, Mumbai, Indi
Sektori-
Uebsajtisunpharma.com